Ligand Pharmaceuticals Inc (LGNZZ) — 8-K Filings

8-K Filings (26)

• Ligand Pharmaceuticals Files 8-K for Regulation FD Disclosure — Dec 18, 2025 Risk: low
  Ligand Pharmaceuticals Inc. announced on December 18, 2025, a current report filing (8-K) with the SEC. The filing pertains to Regulation FD Disclosure and was
• 8-K Filing — Nov 6, 2025
• Ligand Pharmaceuticals Enters Material Definitive Agreement — Sep 16, 2025 Risk: medium
  Ligand Pharmaceuticals Inc. entered into a material definitive agreement on September 12, 2025. This agreement also created a direct financial obligation for th
• Ligand Pharma Reports Material Agreement, Financial Obligations — Aug 14, 2025 Risk: medium
  On August 11, 2025, Ligand Pharmaceuticals Incorporated entered into a material definitive agreement related to its financial obligations. The company also repo
• Ligand Pharmaceuticals Enters Material Definitive Agreement — Aug 11, 2025 Risk: medium
  Ligand Pharmaceuticals Inc. announced on August 11, 2025, the entry into a material definitive agreement. The filing also includes other events and financial st
• Ligand Pharmaceuticals Files 8-K on Financials — Aug 7, 2025 Risk: low
  Ligand Pharmaceuticals Inc. filed an 8-K on August 7, 2025, reporting on its Results of Operations and Financial Condition. The filing includes financial statem
• Ligand Pharmaceuticals Files 8-K — Jul 2, 2025 Risk: low
  Ligand Pharmaceuticals Inc. filed an 8-K on July 2, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contai
• Ligand Pharmaceuticals Files 8-K on Shareholder Vote — Jun 9, 2025 Risk: low
  Ligand Pharmaceuticals Inc. filed an 8-K on June 9, 2025, to report on a submission of matters to a vote of security holders. The filing does not contain specif
• Ligand Pharmaceuticals Files 8-K on Financials — May 8, 2025 Risk: low
  Ligand Pharmaceuticals Inc. filed an 8-K on May 8, 2025, reporting on its Results of Operations and Financial Condition. The filing includes financial statement
• Ligand Pharmaceuticals Files 8-K Current Report — Apr 17, 2025 Risk: low
  Ligand Pharmaceuticals Inc. filed an 8-K on April 17, 2025, reporting an event on April 16, 2025. The filing is a current report under Section 13 or 15(d) of th
• Ligand Pharmaceuticals Files 8-K on Financials — Feb 27, 2025 Risk: low
  Ligand Pharmaceuticals Inc. filed an 8-K on February 27, 2025, reporting on its Results of Operations and Financial Condition. The filing includes financial sta
• Ligand Pharmaceuticals Enters Material Definitive Agreement — Feb 25, 2025 Risk: medium
  Ligand Pharmaceuticals Inc. announced on February 24, 2025, that it entered into a material definitive agreement. The company, headquartered in San Diego, Calif
• Ligand Pharmaceuticals Files 8-K on Financials — Nov 7, 2024 Risk: low
  Ligand Pharmaceuticals Inc. filed an 8-K on November 7, 2024, reporting on its results of operations and financial condition. The filing includes financial stat
• Ligand Pharmaceuticals Files 8-K on Financials — Aug 6, 2024 Risk: low
  Ligand Pharmaceuticals Inc. filed an 8-K on August 6, 2024, reporting on its results of operations and financial condition. The filing includes financial statem
• Ligand Pharmaceuticals Appoints New Chief Medical Officer — Aug 2, 2024 Risk: low
  Ligand Pharmaceuticals Inc. announced on August 2, 2024, the appointment of Dr. Jason L. Adlakha as its new Chief Medical Officer. Dr. Adlakha previously served
• Ligand Pharmaceuticals Completes Asset Acquisition — Jul 17, 2024 Risk: medium
  On July 15, 2024, Ligand Pharmaceuticals Inc. announced the completion of its acquisition of assets from a third party. The filing does not disclose specific de
• Ligand Pharmaceuticals Enters New Loan Agreement — Jul 10, 2024 Risk: medium
  On July 8, 2024, Ligand Pharmaceuticals Inc. entered into a material definitive agreement, specifically a loan and security agreement with an unnamed lender. Th
• Ligand Pharmaceuticals Announces Material Definitive Agreement — Jul 8, 2024 Risk: medium
  On July 8, 2024, Ligand Pharmaceuticals Inc. announced a material definitive agreement. The company also provided a Regulation FD disclosure and filed financial
• Ligand Pharmaceuticals Acquires Avista Therapeutics for $100M Upfront — Jun 27, 2024 Risk: medium
  On June 27, 2024, Ligand Pharmaceuticals Inc. announced the closing of its previously disclosed acquisition of all outstanding shares of Avista Therapeutics, In
• Ligand Pharmaceuticals Appoints New CFO, Todd Simon — Jun 18, 2024 Risk: low
  On June 18, 2024, Ligand Pharmaceuticals Inc. announced the appointment of Todd Simon as its new Chief Financial Officer, effective July 1, 2024. Simon will suc
• Ligand Pharma Moves HQ, Elects Directors — Jun 17, 2024 Risk: low
  Ligand Pharmaceuticals Inc. announced on June 14, 2024, a change in its principal executive offices from San Diego, CA to Jupiter, Florida. The company also rep
• Thermo Fisher to Acquire Ligand Pharma for $7.2B — May 30, 2024 Risk: low
  Ligand Pharmaceuticals Inc. announced on May 29, 2024, that it has entered into a definitive agreement to be acquired by Thermo Fisher Scientific Inc. for $7.2
• Ligand Pharmaceuticals Enters Material Definitive Agreement — May 7, 2024 Risk: medium
  On May 6, 2024, Ligand Pharmaceuticals Inc. entered into a material definitive agreement. The filing does not disclose the specific details of this agreement, s
• Ligand Pharmaceuticals Relocates Executive Offices — Apr 19, 2024 Risk: low
  Ligand Pharmaceuticals Inc. filed an 8-K on April 19, 2024, reporting a change in its principal executive offices from San Diego, California to Jupiter, Florida
• Ligand Pharma Files 8-K on Financial Results and Operations — Feb 27, 2024 Risk: low
  Ligand Pharmaceuticals Incorporated filed an 8-K on February 27, 2024, to report its Results of Operations and Financial Condition, along with Financial Stateme
• Ligand Pharma Files Routine 8-K on Jan 5, No Major News — Jan 8, 2024
  Ligand Pharmaceuticals Inc. filed an 8-K on January 8, 2024, reporting an "Other Event" that occurred on January 5, 2024. This filing is a routine disclosure in

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX